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T
he comment that Dr. Stanton found extraordi-
nary reads as follows: “Collectively, these ﬁndings
prove that reduced SGLT-2 activity—whether
genetically or experimentally induced—is efﬁ-
cacious and relatively safe ..” (1). This sentence referred
to the animal studies described in the preceding paragraph,
as becomes even more apparent in the following sentence
that reads: “The development of SGLT-2 inhibition as a
therapeutic target in type 2 diabetes is therefore logical and
attractive” (2). Possibly, I should have made this clearer.
On the other hand, nowhere else in the commentary do I
extend judgment of efﬁcacy or safety to pharmacological
SGLT-2 inhibition in patients with diabetes. No SGLT-2
inhibitor is currently approved for use in humans, and
several members in the class are being tested for both
comparative efﬁcacy and safety in clinical development
programs that are in good part published or in the public
domain, allowing all interested readers to be well informed.
Dr. Stanton is “even more disturbed” by my declaration
of absence of potential conﬂict of interest. Here, I am
afraid I can only conﬁrm what I stated. The article was
not an editorial—which typically expresses an editorial
stance—but a commentary, which is expected to carry
free opinion. It was proposed by the journal editors and
not commissioned by the pharmaceutical industry. It was
written by myself and not a medical writer, and I signed it
in single name and, therefore, on full accountability for
every word in it. There is no conﬂict of interest whatsoever
pertaining to the views expressed in this commentary.
Having been—and continuing to be—involved with clinical
studies of efﬁcacy (ref. 13 in the commentary) and mode of
action (currently under way) of these pharmacological
tools does not invalidate or negate a single sentence in the
commentary; it is a sign of interest and not a conﬂict of
interest. If anything, the ﬁnal paragraphs highlight what is
unknown about the physiological responses to pharma-
cologically induced glycosuria. In the clinical study cited
as ref. 13—a fortiori sponsored by the drug company pro-
ducing the compound under patent—Dr. Stanton will ﬁnd
duality of interest duly acknowledged.
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